From: Sleep disturbance, depression and pain in adults with sickle cell disease
Demographic Variables | BDI < 17 | BDI ≥ 17 | p 1 | PSQI < 6 | PSQI ≥ 6 | p 1 | ||||
---|---|---|---|---|---|---|---|---|---|---|
 | N | Median (IQR) 2 | N | Median (IQR) 2 |  | N | Median (IQR) 2 | N | Median (IQR) 2 |  |
Age | 250 | 34 (27–47) | 65 | 35 (27–45) | .95 | 90 | 31 (23–45) | 223 | 36 (29–47) | .009 |
BMI (kg/m2) | 245 | 24 (22–27) | 63 | 24 (21–27) | .12 | 89 | 23 (20–27) | 217 | 24 (22–28) | .016 |
Female, N (%) | 250 | 119 (48) | 65 | 40 (62) | .052 | 90 | 42 (47) | 223 | 118 (53) | .32 |
SS/Sβ0 thalassemia, N (%) | 250 | 212 (85) | 65 | 53 (82) | .57 | 90 | 78 (87) | 223 | 184 (83) | .40 |
Clinical History | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Headache, N (%) | 250 | 92 (37) | 64 | 36 (53) | .007 | 90 | 24 (27) | 222 | 105 (47) | <.001 |
Stroke, N (%) | 230 | 32 (14) | 56 | 6 (11) | .66 | 81 | 14 (17) | 204 | 23 (11) | .18 |
Acute Chest Syndrome, N (%) | 248 | 201 (81) | 65 | 52 (80) | .86 | 90 | 70 (78) | 223 | 184 (83) | .34 |
Hydroxyurea therapy, N (%) | 250 | 120 (48) | 65 | 31 (48) | >.99 | 90 | 42 (47) | 223 | 106 (48) | .90 |
Mild + Moderate Pain (days) | 244 | 11 (2–72) | 60 | 25 (4–126) | .040 | 88 | 4 (2–24) | 214 | 23 (4–120) | <.001 |
Severe + Extreme Pain (events) | 250 | 2 (0–5) | 65 | 3 (0–10) | .009 | 90 | 0 (0–2) | 223 | 3 (0–9) | <.001 |
Current Narcotic Use, N (%) | 250 | 159 (64) | 65 | 47 (72) | .24 | 90 | 53 (59) | 223 | 153 (69) | .11 |
Laboratory Measures | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Hemoglobin (g/dL) | 250 | 9.1 (7.8-10.4) | 65 | 8.5 (7.4-9.8) | .050 | 90 | 9.3 (8.1-10.4) | 223 | 8.9 (7.6-10.3) | .20 |
Hemoglobin F (%) | 250 | 5.7 (1.9-12.5) | 65 | 6.0 (3.1-10.7) | .97 | 90 | 5.1 (1.8-13.2) | 223 | 6.0 (2.7-11.7) | .76 |
Oxygen Saturation (%) | 248 | 97 (95–99) | 65 | 97 (95–99) | .97 | 89 | 98 (96–99) | 222 | 97 (95–99) | .093 |